News
Zacks Investment Research on MSN10h
MRNA Beats on Q2 Earnings & Sales, Stock Down on Lowered Sales View
Moderna MRNA incurred a loss of $2.13 per share in the second quarter of 2025, narrower than the Zacks Consensus Estimate of ...
Moderna Inc. shares declined as the company’s cost-cutting efforts failed to assuage investors who are worried about the ...
(NASDAQ:MRNA) today reported financial results and provided business updates for the second quarter of 2025. "In the last three months, we advanced our pipeline with positive Phase 3 flu vaccine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback